Literature DB >> 10780881

Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein.

T K Bera1, P E Kennedy, E A Berger, C F Barbas, I Pastan.   

Abstract

BACKGROUND: 3B3 is a high-affinity anti-gp120 antibody that neutralizes a wide range of primary and laboratory isolates of HIV-1. The parental antibody was isolated from a combinatorial phage display library constructed from bone marrow RNA of an HIV-infected individual. We have generated a highly active immunotoxin using the 3B3 single-chain Fv (scFv) which can specifically kill lymphocytes infected by HIV-1.
MATERIALS AND METHODS: We used recombinant DNA technology to clone the Fv fragment of 3B3 and produce a single-chain Fv (scFv). 3B3 scFv was then fused to a truncated version of Pseudomonas exotoxin A (PE38), giving rise to a recombinant immunotoxin 3B3(Fv)-PE38 that was expressed in E. coli and purified to near homogeneity.
RESULTS: 3B3(Fv)-PE38 binds with the same affinity as the parental Fab antibody to the MN strain of gp120. The immunotoxin specifically kills a gp120-expressing transfected cell line and a chronically HIV-infected lymphocytic cell line. The immunotoxin is very stable at 37 degrees C, retaining 80% of its original activity after 24 hr.
CONCLUSIONS: Potent immunotoxins such as 3B3(Fv)-PE38 could be utilized in combination with multidrug cocktails that limit viral replication to help reduce viral reservoirs in patients with AIDS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10780881      PMCID: PMC2230270     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  24 in total

1.  Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection.

Authors:  W Cavert; D W Notermans; K Staskus; S W Wietgrefe; M Zupancic; K Gebhard; K Henry; Z Q Zhang; R Mills; H McDade; C M Schuwirth; J Goudsmit; S A Danner; A T Haase
Journal:  Science       Date:  1997-05-09       Impact factor: 47.728

2.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

Review 3.  Immunotoxins: an update.

Authors:  G R Thrush; L R Lark; B C Clinchy; E S Vitetta
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

4.  Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.

Authors:  V K Chaudhary; T Mizukami; T R Fuerst; D J FitzGerald; B Moss; I Pastan; E A Berger
Journal:  Nature       Date:  1988-09-22       Impact factor: 49.962

5.  Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes.

Authors:  F W Studier; B A Moffatt
Journal:  J Mol Biol       Date:  1986-05-05       Impact factor: 5.469

6.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

Review 7.  Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.

Authors:  Y Reiter; U Brinkmann; B Lee; I Pastan
Journal:  Nat Biotechnol       Date:  1996-10       Impact factor: 54.908

8.  Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin.

Authors:  L H Pai; R Wittes; A Setser; M C Willingham; I Pastan
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli.

Authors:  J Hwang; D J Fitzgerald; S Adhya; I Pastan
Journal:  Cell       Date:  1987-01-16       Impact factor: 66.850

View more
  17 in total

1.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta.

Authors:  Sergey A Trushin; Gary D Bren; Susana Asin; Kevin N Pennington; Carlos V Paya; Andrew D Badley
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 3.  Eradicating HIV-1 infection: seeking to clear a persistent pathogen.

Authors:  Nancie M Archin; Julia Marsh Sung; Carolina Garrido; Natalia Soriano-Sarabia; David M Margolis
Journal:  Nat Rev Microbiol       Date:  2014-11       Impact factor: 60.633

4.  Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.

Authors:  Michael J Root; Dean H Hamer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

5.  Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Authors:  Edward A Berger; Ira Pastan
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

6.  Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

Authors:  Julia A M Sung; Joy Pickeral; Liqin Liu; Sherry A Stanfield-Oakley; Chia-Ying Kao Lam; Carolina Garrido; Justin Pollara; Celia LaBranche; Mattia Bonsignori; M Anthony Moody; Yinhua Yang; Robert Parks; Nancie Archin; Brigitte Allard; Jennifer Kirchherr; JoAnn D Kuruc; Cynthia L Gay; Myron S Cohen; Christina Ochsenbauer; Kelly Soderberg; Hua-Xin Liao; David Montefiori; Paul Moore; Syd Johnson; Scott Koenig; Barton F Haynes; Jeffrey L Nordstrom; David M Margolis; Guido Ferrari
Journal:  J Clin Invest       Date:  2015-09-28       Impact factor: 14.808

Review 7.  Regulation of HIV-1 latency by T-cell activation.

Authors:  Samuel A Williams; Warner C Greene
Journal:  Cytokine       Date:  2007-07-20       Impact factor: 3.861

Review 8.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

9.  Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages.

Authors:  Matthew D Marsden; Jie Xu; Dean Hamer; Jerome A Zack
Journal:  AIDS Res Hum Retroviruses       Date:  2008-11       Impact factor: 2.205

Review 10.  Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.

Authors:  Jeffrey C Umotoy; Steven W de Taeye
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.